TO CORRECT OR NOT TO CORRECT (FOR TREATMENT): ESTIMATING PRETREATMENT LDL-C CONCENTRATIONS IN GENETICALLY CHARACTERIZED PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA ON LIPID-LOWERING MEDICATION

被引：0
|
作者：
Stevens, Christophe [1 ]
Elshorbagy, Amany [1 ]
Vallejo-Vaz, Antonio [1 ,2 ,3 ,4 ]
Dharmayat, Kanika [1 ]
Lyons, Alexander [1 ]
Bourbon, Mafalda [5 ,6 ,7 ]
Chora, Joana [6 ,7 ]
Humphries, Steve [8 ]
Catapano, Alberico [9 ,10 ]
Hovingh, G. [11 ]
Mata, Pedro [12 ]
Santos, Raul [13 ]
Soran, Handrean [14 ]
Watts, Gerald [15 ,16 ]
Raal, Frederick J. [17 ]
Freiberger, Tomas [18 ]
Ray, Kausik [1 ]
机构：
[1] Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, Imperial Ctr Cardiovasc Dis Prevent, London, England
[2] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER Epidemiol & Salud Pub, Seville, Spain
[3] Univ Seville, Dept Med, Fac Med, Seville, Spain
[4] Univ Seville, Inst Biomedicina Sevilla, Clin Epidemiol & Vasc Risk, CSIC,IBiS Hosp Univ Virgen del Rocio, Seville, Spain
[5] Inst Nacl Saude Doutor Ricardo Jorge, Unidade Invest & Desenvolvimento, Grupo Invest Cardiovasc, Dept Promocao Saude & Prevencao Doencas Nao Trans, Lisbon, Portugal
[6] Univ Lisbon, BioISI Biosyst & Integrat Sci, Fac Ciencias, Lisbon, Portugal
[7] Inst Nacl Saude Doutor Ricardo Jorge, Lisbon, Portugal
[8] UCL, Inst Cardiovasc Sci, London, England
[9] Epidemiol & Prevent Pharmacol Serv SEFAP, Dept Pharmacol & Biomol Sci, Milan, Italy
[10] IRCCS MultiMed, Sesto San Giovanni, MI, Italy
[11] Amsterdam UMC, Vasc Med, Amsterdam, Netherlands
[12] Fdn Hipercolesterolemia Familiar, Madrid, Spain
[13] Univ Sao Paulo, Cardiopneumol, Sao Paulo, Brazil
[14] Manchester Univ NHS Fdn Trust, Manchester, England
[15] Univ Western Australia, Sch Med, Perth, Australia
[16] Univ Western Australia, Cardiometab Serv, Sch Med, Perth, Australia
[17] Univ Witwatersrand, Carbohydrate & Lipid Metab Res Unit, Fac Hlth Sci, Johannesburg, South Africa
[18] Masaryk Univ, Ctr Cardiovasc Surg & Transplantat, Brno, Czech Republic
来源：
ATHEROSCLEROSIS | 2024年 / 395卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SaaG031
引用
收藏
页数：2
相关论文
共 29 条
  • [11] ACHIEVEMENT OF LDL-C GOALS IN PATIENTS AT MODERATE TO VERY HIGH CARDIOVASCULAR RISK ON LIPID-LOWERING DRUG THERAPY (CEPHEUS II)
    Logunova, Natalia
    Gurina, Natalia
    Boytsov, Sergey
    [J]. ATHEROSCLEROSIS, 2017, 263 : E236 - E237
  • [12] VARIABILITY OF THE LDL-C RESPONSE TO TWO INTENSIVE LIPID-LOWERING THERAPY REGIMENS IN PATIENTS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
    Li, Ya
    Jin, Jinhua
    Zhang, Wenbin
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 151 - 151
  • [13] Resource utilization and costs associated with achieved LDL-C levels in patients following a myocardial infarction treated with lipid-lowering therapies in Spain
    Escobar Cervantes, C.
    Campos Tapias, I
    Sorio Vilela, F.
    Lozano, J.
    Kahangire, D. A.
    Sicras-Mainar, A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3545 - 3545
  • [14] Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design
    Boulmpou, Aristi
    Kartas, Anastasios
    Farmakis, Ioannis
    Zafeiropoulos, Stefanos
    Nevras, Vasileios
    Papadimitriou, Ioannis
    Tampaki, Athina
    Vlachou, Anastasia
    Lillis, Leonidas
    Koutsakis, Athanasios
    Karvounis, Haralampos
    Giannakoulas, George
    [J]. HELLENIC JOURNAL OF CARDIOLOGY, 2019, 60 (04) : 249 - 253
  • [15] Assessment of lipid-lowering treatment and LDL-C goal attainment within a managed care population newly diagnosed with coronary heart disease or diabetes mellitus
    Daniel, G
    Bullano, MF
    Nag, S
    Kamal-Bahl, SJ
    Foley, K
    Sajjan, S
    Willey, VJ
    Cziraky, MJ
    Alexander, C
    [J]. CIRCULATION, 2004, 109 (20) : E245 - E245
  • [16] Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China
    Wang, Xing
    He, Yan
    Wang, Tao
    Li, Chunming
    Ma, Zihui
    Zhang, Heng
    Ma, Handong
    Zhao, Hongxin
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (04) : 307 - 315
  • [17] Are coronary patients on lipid-lowering therapy in Europe achieving the recommended LDL-C target? Results from the Dyslipidemia International Study (DYSIS) II Europe
    Gitt, A. K.
    Ferrieres, J.
    De Ferrari, G.
    Elisaf, M.
    Hermans, M. P.
    Kiernan, T.
    Oganov, R.
    Lautsch, D.
    Ashton, V.
    Ambegaonkar, B.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 286 - 286
  • [18] MORE AGGRESSIVE LDL-C AND NON-HDL-C TARGETS MUST BE ACHIEVED IN PATIENTS RECEIVING LIPID-LOWERING THERAPY TO NORMALIZE APOB-CONTAINING LIPOPROTEINS
    Betteridge, J.
    Guyton, J. R.
    Farnier, M.
    Leiter, L. A.
    Lin, J.
    Shah, A.
    Johnson-Levonas, A. O.
    Brudi, P.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 163 - 164
  • [19] Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions
    Zhang, Shuang
    Li, Zhi-Fan
    Shi, Hui-Wei
    Zhang, Wen-Jia
    Sui, Yong-Gang
    Li, Jian-Jun
    Dou, Ke-Fei
    Qian, Jie
    Wu, Na-Qiong
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [20] Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?
    Rallidis, Loukianos S.
    Tsamoulis, Donatos
    Leventis, Ioannis
    Kalogeras, Petros
    Delakis, Iosif
    Samiotis, Elefterios
    Kalantzis, Charalampos
    Malkots, Belkis
    Tasoulas, Dimitrios
    Bouratzis, Vasileios
    Eleutheriou, Dimitris
    Dalos, Styliano
    Potoupni, Victoria
    Zervakis, Stelio
    Xygka, Georgia
    Miliotou, Argyro
    Papathanasiou, Konstantinos A.
    Vlachopoulos, Charalambos
    [J]. KARDIOLOGIA POLSKA, 2023, 81 (10) : 1012 - 1014
123